For more than three decades, Dr. David Smotrich has been pushing the boundaries of reproductive medicine, helping transform fertility treatment from a field of limited possibilities into one defined by innovation, personalization, and hope. As Founder and Medical Director of La Jolla IVF, his work has not only advanced the science of conception but has also helped reshape society’s understanding of what a family can look like.
Throughout his career, Dr. Smotrich has remained at the forefront of groundbreaking reproductive technologies. From helping pioneer blastocyst embryo culture and intracytoplasmic sperm injection (ICSI) to advancing preimplantation genetic testing, egg donation, gestational surrogacy, and fertility preservation, many of the tools now considered standard in modern fertility care were once revolutionary concepts. These advancements have dramatically improved success rates while expanding options for patients facing infertility, age-related reproductive challenges, genetic concerns, or complex family-building circumstances. In 2007, Dr. Smotrich received the American Fertility Association’s Visionary Award, presented by Angela Bassett and Courtney B. Vance, honoring his groundbreaking work in fertility treatment, surrogacy, and reproductive innovation
One of the most significant developments has been the evolution of genetic embryo screening. Today, physicians can evaluate embryos for chromosomal abnormalities before implantation, providing critical insight into viability and helping reduce the emotional and physical burden of repeated unsuccessful cycles. According to Dr. Smotrich, nearly 91 percent of embryos produced by women at age 45 are genetically abnormal, underscoring the importance of precision medicine in reproductive care. Technologies that once seemed futuristic now allow physicians to make more informed decisions, improving outcomes while creating more individualized treatment plans.
Yet Dr. Smotrich’s influence extends far beyond the laboratory.
Long before LGBTQ family-building entered mainstream conversation, he was helping same-sex couples pursue parenthood through assisted reproductive technology. In the mid-1990s, he became one of the earliest fertility specialists in the United States to advocate for gay intended parents, creating pathways to parenthood at a time when legal protections and social acceptance were far from guaranteed.
One of the most defining moments of Dr. Smotrich’s career took place in 1998. He helped a same-sex male-to-male couple get pregnant and have a baby girl. One of the gentlemen, who was a lawyer, worked on his own case and was granted the first parentage judgment for a same-sex couple in a gestational surrogacy case. This groundbreaking achievement challenged existing legal norms and ultimately helped advance broader conversations surrounding parental equality. While reproductive medicine had evolved rapidly, the law had not yet caught up. Dr. Smotrich’s willingness to advocate for his patients placed him at the center of a pivotal moment in LGBTQ family rights, demonstrating that innovation is not always measured solely by scientific breakthroughs, but by the courage to challenge outdated systems.
Today, La Jolla IVF has helped facilitate thousands of LGBTQ family-building journeys and has become an international destination for intended parents seeking expertise in fertility treatment, egg donation, and surrogacy. The practice also serves military veterans, cancer survivors preserving fertility before treatment, single parents by choice, and individuals pursuing parenthood later in life. Regardless of background or circumstance, Dr. Smotrich believes every patient deserves a personalized path forward.
“Science is only part of the equation,” says Dr. Smotrich. “The human side of fertility care matters just as much.”
That philosophy continues to guide his vision for the future. As reproductive medicine enters a new era, Dr. Smotrich and his team are exploring emerging technologies including artificial intelligence, regenerative therapies such as platelet-rich plasma (PRP), and increasingly sophisticated methods of embryo selection. Artificial intelligence has the potential to analyze embryo development patterns with unprecedented precision, while regenerative therapies may offer new possibilities for patients with diminished ovarian reserve or other fertility challenges.
At the same time, fertility medicine continues to raise complex ethical questions surrounding reproductive autonomy, genetic selection, and even the use of reproductive tissue from deceased donors. For Dr. Smotrich, navigating these advancements requires balancing scientific progress with compassion, responsibility, and respect for the deeply personal decisions patients face.
